Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
diarrhea
Biotech
Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win
As Crinetics preps FDA run in rare growth disorder, the same drug has shown potential to treat symptoms associated with a neuroendocrine tumor.
James Waldron
Mar 13, 2024 9:16am
Anatara, ObvioHealth partner for virtual trials in Australia
Oct 4, 2021 12:52pm
MGB tops up cash pool to wrap up antibiotic phase 2a
Aug 30, 2019 9:15am
Gates Foundation’s $100M-a-year nonprofit biotech takes flight
Jun 8, 2018 6:36am
J&J scraps phase 3 antibiotic program acquired in $30B takeover
Apr 17, 2018 9:22am
Novartis, Gates Foundation pen tropical disease drug pact
Feb 14, 2018 4:23am
